

PLEASE READ

**IMPORTANT MEDICINE
SAFETY INFORMATION**

APPROVED
BY THE



08 October 2026

Direct Healthcare Professional Communication (DHPC)

Ocrevus (ocrelizumab): New risk of drug-induced liver injury and recommendations on monitoring of liver function before and during treatment

Dear Healthcare professional,

Roche Products (Ireland) Limited, in agreement with the European Medicines Agency and the Health Products Regulatory Authority (HPRA), would like to inform you of the following:

Summary

- **Drug-induced liver injury, including severe and life-threatening cases, has been identified as a new risk for patients treated with Ocrevus.**
- **Liver function tests (LFTs) should be performed prior to initiating treatment with Ocrevus and prior to the second initial 300 mg infusion.**
- **Patients should be informed by treating physician about signs and symptoms of any hepatic injury during treatment, including but not limited to: new or worsening fatigue, anorexia, nausea, vomiting, right upper abdominal discomfort, dark urine or jaundice.**
- **Patients and caregivers should be advised to immediately seek medical attention if they experience signs or symptoms suggesting liver injury.**
- **LFTs should be performed promptly in any patient who reports symptoms that may indicate liver injury.**

**Roche Products
(Ireland) Limited**

3030 Lake Drive
Citywest Business Campus
Dublin 24
D24 KX6Y,
Ireland
(Registered Office)

Tel: 353-1-4690700
Email:
dublin.reception@roche.com

Registered in Ireland
No. 214337

*Directors: E. Yousef Hassan (Egyptian), M. Elghareeb (Egyptian), J. Cortizo (Swiss), A. Mac Cann
Company Secretary: S. Davis (British)*

PLEASE READ

**IMPORTANT MEDICINE
SAFETY INFORMATION**

APPROVED
BY THE



- **If liver injury is confirmed, Ocrevus should be discontinued. Treatment should not be resumed unless a plausible alternative aetiology for the signs and symptoms of liver injury can be established.**

Background on the safety concern

Ocrevus is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. Ocrevus is indicated for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity. Ocrevus is approved as a twice-yearly 600 mg intravenous dose and a twice-yearly 920 mg subcutaneous dose.

As of 31 October 2025, an estimated total of 451,174 patients with MS have received Ocrevus across a combination of interventional clinical trials, pre-approval access programmes and post-marketing experience. This corresponds to an estimated total cumulative exposure of more than 1,4 million patient-years.

A review of all available data concerning liver injury has concluded that Ocrevus is associated with a risk of drug-induced liver injury.

Temporal association: cases showed strong evidence of a temporal association to the first initial dose of ocrelizumab, with onset typically within one month (prior to and following the 2nd 300mg infusion at day 14).

The majority of cases were not serious but some were severe or life-threatening, with markedly elevated serum aminotransferases and total bilirubin. In a few instances, patients were temporarily placed on transplant lists, but liver injury resolved following treatment resulting in removal from transplant list.

The review of available data concerning liver injury did not identify a clear mechanism.

The product information will be updated to include information on this adverse reaction (frequency category: unknown) and measures to reduce the risk.

Please ensure awareness of the content of this letter within your team.

**Roche Products
(Ireland) Limited**

3030 Lake Drive
Citywest Business Campus
Dublin 24
D24 KX6Y,
Ireland
(Registered Office)

Tel: 353-1-4690700
Email:
dublin.reception@roche.com

Registered in Ireland
No. 214337

*Directors: E. Yousef Hassan (Egyptian), M. Elghareeb (Egyptian), J. Cortizo (Swiss), A. Mac Cann
Company Secretary: S. Davis (British)*

PLEASE READ**IMPORTANT MEDICINE
SAFETY INFORMATION**APPROVED
BY THE**Call for reporting**

Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, website: www.hpra.ie.

Healthcare professionals may also report any suspected adverse reactions to the Drug Surveillance Centre in Roche Products (Ireland) Limited by telephone (01 4690700) or email (Ireland.drug_surveillance_centre@roche.com).

Company contact point

Should you have any questions regarding the use of Ocrevus 300 mg concentrate for solution for infusion or Ocrevus 920 mg solution for injection, please contact us at: Medical Information at Roche Products (Ireland) Limited by telephone (01 4690700) or email (Ireland.druginfo@roche.com). Further information is available from Roche Products (Ireland) Limited, 3030 Lake Drive, Citywest Business Campus, Dublin 24, D24 KX6Y, Ireland.

Yours sincerely,

Signed by:

Maeve McGrath



Signer Name: Maeve McGrath
Signing Reason: I approve this document
Signing Time: 29-Sep-2026 | 3:59:55 PM CEST

B515F6F688534F77B86A59D116D6C4D1

Maeve McGrath
Country Medical Director
Roche Products (Ireland) Limited

Data Protection Statement

Roche Products (Ireland) Limited ("Roche") process your personal data as part of sending this communication to you. Roche may hold and use personal data provided by you and/or obtained by us and disclose it to other companies in the Roche group, to partners (including other Marketing Authorisation holders), agents and service providers of Roche and governmental agencies and bodies for the purposes of complying with Roche's legal obligations. Your personal data may be transferred outside of the European Economic Area, but any transfers shall be made in accordance with data protection law. You have various rights under data protection law, including the rights to access your personal data and to have any inaccuracies in such data corrected or deleted. Please see our privacy notice on www.roche.ie for further details.

**Roche Products
(Ireland) Limited**

3030 Lake Drive
Citywest Business Campus
Dublin 24
D24 KX6Y,
Ireland
(Registered Office)

Tel: 353-1-4690700
Email:
dublin.reception@roche.com

Registered in Ireland
No. 214337

Directors: E. Yousef Hassan (Egyptian), M. Elghareeb (Egyptian), J. Cortizo (Swiss), A. Mac Cann
Company Secretary: S. Davis (British)